Amgen, Humana Use Data From Wearables, Digital Apps to Improve Patient Outcomes

IHS Global Insight

August 22, 2017

Biotechnology firm Amgen and health insurer Humana (both U.S.) have announced a partnership focused on improving health outcomes and efficiency through the use of real-world data from across Humana’s 13 million members. The collaboration would utilize real-world evidence (RWE) with data collected from wearable technology, digital apps, and Bluetooth-enabled drug delivery devices, with the aim of increasing value for patients through identifying areas to improve quality and outcomes with regards to overall healthcare costs. Amgen and Humana will initially work on six projects—focused on cardiovascular disease, osteoporosis, neurologic disorders, inflammatory diseases and cancer—which are currently ongoing, with other projects involving new therapeutic areas anticipated to commence over the course of the agreement. The research would help identify patients likely to experience adverse outcomes, and develop algorithms to predict risk and support early intervention.

Significance: Amgen has participated in more than 75 value-based programs globally; however, this collaboration marks a novel integrated approach to care that will focus on the totality of healthcare costs and benefits with regards to patient care. According to Joshua Ofman, senior vice president of Global Value, Access & Policy at Amgen, “The rising cost of disease is challenging the sustainability of our healthcare system in the U.S., and is motivating innovators to urgently develop new therapeutic options, and partner on opportunities to improve the quality and efficiency of care and reduce financial burden to the system.” Meanwhile, Humana’s chief pharmacy officer, Laura Happe, noted that the partnership could yield “new tools and technology that support our provider partners who are on the journey to population health and value-based care.” According to Humana, the insurer lowered costs by 20% in 2015 for members treated by providers implementing value-based reimbursement models versus the fee-for-service Medicare cost model.

Original headline: Amgen, Humana collaborate on value-based initiative to improve patient outcomes across multiple therapeutic areas

Copyright 2017 IHS Global Insight. All Rights Reserved.

Copyright © LexisNexis, a division of Reed Elsevier Inc. All rights reserved.  
Terms and Conditions    Privacy Policy

Quality News Today is an ASQ member benefit offering quality related news
from around the world every business day.

ASQ is a global community of people passionate about quality, who use the tools, their ideas and expertise to make our world work better. ASQ: The Global Voice of Quality.